Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 231 - 240 of 278

Selected Filters:
29 July 2022

National Guidelines for Prevention of Mother to Child Transmission of HIV, Syphilis, and Hepatitis B Virus

Ethiopia has been in directly implementing and optimizing their prevention of mother to child transmission (PMTCT) program since 2001. The 2021 version of these guidelines focus on eliminating HIV, Hepatitis B, and Syphilis in line with 2016 World Health Organization (WHO) goals to eliminate transmission of these diseases to newborns. This set of guidelines addresses…

Normative Guidance/Policies

Document
29 July 2022

Ethiopia HIV/AIDS National Strategic Plan 2021-25

The National Strategic Plan aims to achieve maximum public health impact by addressing key drivers of the epidemic, shifting to a people-focused response, focusing on key and priority populations, and more.

Normative Guidance/Policies

Document
29 July 2022

Kenya HIV Prevention Revolution Road Map

This document outlines a new approach toward HIV prevention by the Kenyan government, including a local approach to prevention, moving away from silos toward combination prevention, focusing on key populations, and more.

Normative Guidance/Policies

Document
14 July 2022

Tanzania National Guidelines for Comprehensive Package of HIV Interventions for Key & Vulnerable Populations, 2017

With the global 2030 goal to eliminate HIV, the Government of Tanzania is working to support those most in need of HIV prevention and treatment services. These national guidelines standardize the implementation of a comprehensive HIV prevention and treatment services for Key and Vulnerable Populations (KVP).

Normative Guidance/Policies

Document
14 July 2022

Social and Behaviour Change Communication Strategy for Sexual & Reproductive Health, Rights & HIV in Lesotho 2020-21 to 2022-23

Lesotho's Social and Behaviour Change Communication Strategy is a strategic response to the high levels of HIV and TB prevalence in the country that are exacerbated by the persistence of structural and sio-economic difficulties, such as poverty, unemployment, gender inequality and more. This strategy aims to address these issues.

Research, Normative Guidance/Policies

Document
7 July 2022

Synthesis of Post-Exposure Prophylaxis (PEP) Policies in MOSAIC Countries

This brief summarizes the PEP policy landscape, how to address barriers to policy and implementation, and provides recommendations to increase PEP uptake as part of HIV prevention. While it focuses on countries within the MOSAIC consortium, the findings are broadly applicable for ministries of health, implementing partners, providers, and potential PEP users alike.

Normative Guidance/Policies

Document
7 July 2022

FDA approves first drug for reducing the risk of sexually acquired HIV infection

This article from July 16, 2012 announces the U.S. Food and Drug Administration's approval of Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners.

Normative Guidance/Policies

External Link
7 July 2022

WHO PrEP Implementation Tool App

The Oral PrEP eLearning Resource Package (eLRP) introduces health care providers to Oral PrEP for HIV infection. The eLRP includes eLearning courses for clinicians with an accompanying Oral PrEP Implementation Tool App.

Normative Guidance/Policies

External Link
7 July 2022

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

External Link
7 July 2022

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

This article announces the U.S. Food and Drug Administration's approval of Descovy in at-risk adults and adolescents for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection from sex, excluding those who have receptive vaginal sex.

Normative Guidance/Policies

External Link